Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Panacea-Biotec-Ltd"

2 News Found

Reliance Life Sciences appoints Siva Sankar Mahamkali as VP Biosimilars Manufacturing Operations
People | May 22, 2026

Reliance Life Sciences appoints Siva Sankar Mahamkali as VP Biosimilars Manufacturing Operations

Biologics manufacturing veteran brings over two decades of expertise in biosimilars, GMP operations, and large-scale biopharmaceutical manufacturing

Panacea Biotec posts consolidated Q4FY21 loss of Rs. 54.14 crore
News | June 03, 2021

Panacea Biotec posts consolidated Q4FY21 loss of Rs. 54.14 crore

The company reported total income of Rs.634.79 crores during the 12 months period ended March 31, 2021

Upcoming E-conference
July 17, 2026 Biosimilars & Biologics: The Next Growth Frontiers for Indian Pharma

Latest Stories

Zealand Pharma’s petrelintide delivers double-digit weight loss in next-gen obesity treatment

Teva study shows Huntington’s disease treatment improves life for patients & caregivers

Oval & Merck Specialities sign strategic pact to expand access to advanced IVF care in India

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International
Cancer treatment must move beyond one-size-fits-all decisions: Dr. Manjiri Bakre, CEO and Founder, OncoStem Diagnostics
Cancer treatment must move beyond one-size-fits-all decisions: Dr. Manjiri Bakre, CEO and Founder, OncoStem Diagnostics
Dr. Manjiri Bakre CEO and Founder, OncoStem Diagnostics
We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene
We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene
Akhil Ravi Chief Executive Officer, Aurigene Pharmaceutical Services Limited

Packaging